Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Chen TL;Chen TL; Chang WC; Kuo SC; Lee YT; Chen CP; Siu LK; Cho WL; Fung CP
  • Source:
    Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2010 Aug; Vol. 54 (8), pp. 3107-12. Date of Electronic Publication: 2010 Jun 01.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, American Society for Microbiology
    • Subject Terms:
    • Abstract:
      The contribution of the blaOXA-58 gene and its promoter to beta-lactam resistance has not been validated in Acinetobacter spp. other than Acinetobacter baumannii. We identified a multidrug-resistant (including carbapenem resistance) Acinetobacter genomic species 13TU in which blaOXA-58 was the only detected carbapenemase gene. The blaOXA-58 gene was plasmid located, flanked by ISAba3 (downstream) and an ISAba3-like element (upstream). An IS1006 element was inserted into ISAba3-like (IS1006-DeltaISAba3-like) to generate a hybrid promoter for blaOXA-58, with a -35 promoter located in IS1006 and a -10 promoter in ISAba3-like. The reference strain of Acinetobacter genomic species 13TU, ATCC 17903, revealed higher MICs of amoxicillin, ticarcillin, and piperacillin and heteroresistance to imipenem and meropenem when it was transformed with a shuttle vector containing a fragment encompassing DeltaISAba3-like-blaOXA-58, compared to the same host containing only blaOXA-58. When the fragment was changed from DeltaISAba3-like-blaOXA-58 to IS1006-DeltaISAba3-like-blaOXA-58, the ATCC 17903 transformant revealed a markedly higher level of blaOXA-58 transcription (12-fold), increased cefuroxime and piperacillin-tazobactam MICs, and homoresistance to imipenem and meropenem. Different roles of the insertion elements preceding the blaOXA-58 gene in Acinetobacter genomic species 13TU are demonstrated. The ISAba3-like--blaOXA-58 construct can mediate resistance to penicillin derivatives but only heteroresistance to carbapenems. The insertion of IS1006 into ISAba3-like, generating a hybrid promoter, could further enhance the transcription of blaOXA-58 and mediate homoresistance to carbapenems and also enhanced resistance to piperacillin-tazobactam.
    • References:
      Int J Antimicrob Agents. 2010 May;35(5):439-43. (PMID: 20106635)
      Antimicrob Agents Chemother. 2010 Jan;54(1):24-38. (PMID: 19721065)
      Antimicrob Agents Chemother. 2007 Jul;51(7):2324-8. (PMID: 17438042)
      Microbiology (Reading). 2004 Apr;150(Pt 4):979-992. (PMID: 15073307)
      Antimicrob Agents Chemother. 2009 Dec;53(12):5035-8. (PMID: 19770279)
      Antimicrob Agents Chemother. 2003 May;47(5):1536-42. (PMID: 12709319)
      Clin Microbiol Infect. 2006 Sep;12(9):826-36. (PMID: 16882287)
      Nat Rev Microbiol. 2007 Dec;5(12):939-51. (PMID: 18007677)
      J Clin Microbiol. 2005 Apr;43(4):1632-9. (PMID: 15814977)
      J Antimicrob Chemother. 2009 Apr;63(4):828-30. (PMID: 19223304)
      Antimicrob Agents Chemother. 2008 May;52(5):1613-7. (PMID: 18299404)
      Clin Microbiol Infect. 2007 Dec;13(12):1199-201. (PMID: 17850345)
      Int J Antimicrob Agents. 2006 Apr;27(4):351-3. (PMID: 16564159)
      Antimicrob Agents Chemother. 2008 Jul;52(7):2573-80. (PMID: 18443121)
      Clin Microbiol Rev. 2008 Jul;21(3):538-82. (PMID: 18625687)
      Antimicrob Agents Chemother. 2008 Nov;52(11):4115-20. (PMID: 18725447)
      Antimicrob Agents Chemother. 2008 Aug;52(8):2955-8. (PMID: 18505859)
      Diagn Microbiol Infect Dis. 2008 Aug;61(4):468-70. (PMID: 18485655)
      Antimicrob Agents Chemother. 2006 Apr;50(4):1442-8. (PMID: 16569863)
      J Clin Microbiol. 2006 Sep;44(9):3139-44. (PMID: 16954239)
      Antimicrob Agents Chemother. 2008 Jul;52(7):2616-25. (PMID: 18411315)
      Plasmid. 2006 Sep;56(2):112-23. (PMID: 16530832)
      Antimicrob Agents Chemother. 2009 Jul;53(7):3010-6. (PMID: 19380596)
      J Antimicrob Chemother. 2007 Feb;59(2):321-2. (PMID: 17185300)
      Int J Antimicrob Agents. 2009 Dec;34(6):580-4. (PMID: 19733035)
      Antimicrob Agents Chemother. 2006 Jan;50(1):399-400. (PMID: 16377723)
      J Infect Dis. 2002 Dec 1;186(11):1677-81. (PMID: 12447747)
      Antimicrob Agents Chemother. 2009 Aug;53(8):3528-33. (PMID: 19487447)
      J Antimicrob Chemother. 2007 Apr;59(4):633-9. (PMID: 17339277)
      Antimicrob Agents Chemother. 2005 Aug;49(8):3198-202. (PMID: 16048925)
    • Molecular Sequence:
      GENBANK GU327621
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Carbapenems)
      0 (DNA Transposable Elements)
      87-53-6 (Penicillanic Acid)
      EC 3.5.2.6 (beta-Lactamases)
      SE10G96M8W (Tazobactam)
      X00B0D5O0E (Piperacillin)
    • Publication Date:
      Date Created: 20100603 Date Completed: 20101124 Latest Revision: 20220408
    • Publication Date:
      20231215
    • Accession Number:
      PMC2916316
    • Accession Number:
      10.1128/AAC.00128-10
    • Accession Number:
      20516281